经导管主动脉瓣置换术后再次手术:10年经验带来的启示
该研究回顾了2011至2022年间66例TAVR术后再次手术患者,其中自体瓣TAVR组42例(63.6%),瓣中瓣TAVR(VIV-TAVR)组24例(36.4%)。自体瓣TAVR组再次手术难度指数评分显著更高(2.0 vs 1.0分;P < .001),手术死亡率有更高趋势(14.2% vs 0%;P = .079)。自体瓣TAVR组8年再次手术累积发生率低于VIV-TAVR组(1.9% vs 14.1%;亚分布风险比8.0;95% CI,4.1-15.9;P < .001)。
要点
- 2021年TAVR时低/中危患者比例已超过高/极高危患者。
- 自体瓣TAVR组再次手术难度指数评分显著高于VIV-TAVR组(2.0 vs 1.0分;P < .001)。
- 自体瓣TAVR组8年再次手术累积发生率低于VIV-TAVR组(1.9% vs 14.1%;亚分布风险比8.0;95% CI,4.1-15.9;P < .001)。
核心结论
- 低/中危患者正成为需要再次手术的主要群体。
- 自体瓣TAVR与较低的植入后再次介入率相关,但再次手术技术难度和死亡率更高。
- VIV-TAVR与较高的再次介入率相关,但再次手术技术难度和死亡率较低。
研究设计与样本
- 单中心10年经验回顾性研究,纳入2011年至2022年间66例TAVR术后再次手术患者。
- 其中自体瓣TAVR组42例(63.6%),VIV-TAVR组24例(36.4%)。
主要发现
- 2021年TAVR时低/中危组患者比例超过高/极高危组。
- 自体瓣TAVR组使用的TAVR瓣膜更大,且TAVR时低危状态比VIV-TAVR组更常见。
- 再次手术中合并手术非常普遍,单纯外科主动脉瓣置换仅占整个队列的18.2%。
- 自体瓣TAVR组再次手术难度指数评分显著高于VIV-TAVR组(2.0 vs 1.0分;P < .001),手术死亡率有更高趋势(14.2% vs 0%;P = .079)。
- 自体瓣TAVR组8年再次手术累积发生率为1.9%,VIV-TAVR组为14.1%(亚分布风险比8.0;95% CI,4.1-15.9;P < .001);合并再次手术和再次TAVR的瓣膜再介入累积发生率分别为3.3%和19.0%(亚分布风险比6.2;95% CI,3.6-10.9;P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Use of transcatheter aortic valve replacement (TAVR) has demonstrated dramatic growth in the past decade. This study aims to investigate implications of post-TAVR reoperation from our 10-year experience. METHODS: Between 2011 and 2022, 66 post-TAVR patients underwent a reoperation, consisting of 42 (63.6%) patients with native TAVR and 24 (36.4%) patients with valve-in-valve TAVR (VIV-TAVR) after surgical aortic valve replacement. RESULTS: The aggregate proportion of patients belonging to the low-/intermediate-risk group at the time of TAVR exceeded that of the high-/extreme-risk cohort in 2021. The native TAVR group received a larger TAVR valve, whereas more frequent low-risk status at the time of TAVR than the VIV-TAVR group. Concurrent procedures were highly common during reoperation and isolated surgical aortic valve replacement represented only 18.2% of the entire cohort. The native TAVR group demonstrated significantly higher TAVR explant difficulty index score (2.0 vs 1.0 points; P < .001) and operative mortality (14.2% vs 0%; P = .079) compared with the VIV-TAVR group. The 8-year cumulative incidence of reoperation was 1.9% and 14.1% (subdistribution hazard ratio, 8.0; 95% CI, 4.1-15.9; P < .001) in the native and VIV-TAVR group, respectively. Furthermore, cumulative incidence of valve reintervention, combining reoperations and redo TAVRs, was 3.3% and 19.0% (subdistribution hazard ratio, 6.2; 95% CI, 3.6-10.9; P < .001). CONCLUSIONS: Low-/intermediate-risk patients are emerging as the predominant group necessitating reoperations. Native TAVR was associated with lower postimplant reintervention rates, albeit with higher reoperative technical difficulty and mortality. Conversely, VIV-TAVR was associated with higher reintervention, but demonstrated lower technical difficulty and mortality for reoperation.
引用
- Fukuhara S, Kim KM, Yang B, et al. Reoperation following transcatheter aortic valve replacement: Insights from 10 years' experience. J Thorac Cardiovasc Surg. 2023. PMID: 37164056. doi:10.1016/j.jtcvs.2023.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。